



COMBATTING URGENT VIRAL DISEASE THREATS

Dr David Foster, CEO & Managing Director

January 2026

ASX: ILA



ISLAND PHARMACEUTICALS (ASX: ILA)

TWO PROGRAMS TARGETING INFECTIOUS DISEASES



Two, well advanced clinical stage programs



Major market potential via both programs



Both assets have Priority Review Voucher potential



Phase 2a/b PROTECT clinical trial in dengue complete




Positive FDA feedback on Animal Rule regulatory path



Multiple near term clinical trial, operational and regulatory catalysts

CORPORATE OVERVIEW



Share on issue ¹ :	269,052,397
Price per share ¹ :	\$0.43
Market capitalisation ¹ :	\$115.7m
Cash at bank (31 December 2025) ² :	\$6.87m
Potential additional capital from vested options where current share price exceeds exercise price:	~\$3m
Debt:	Nil

Price & volume (12 months)



Substantial shareholders

Dr William James Garner ³	15.50%
Jason Alan Carroll ³	11.92%
MWP Partners Limited ⁴	8.25%
Dr Daniel Tillett ³	7.80%

Board of Directors

Jason Carroll, Non-Executive Chairman
Dr David Foster, CEO & Managing Director
Chris Ntoumenopoulos , Non-Executive Director

1. As at 23 January 2026
2.Does not take into consideration cash movement since reporting date
3 Per holding per Substantial interest notice lodged with ASX on 9 December 2025
4 Per holding per Substantial interest notice lodged with ASX on 3 June 2025



COMPANY OVERVIEW

- Two clinical stage assets – Galidesivir and ISLA-101 - both with Priority Review Voucher potential based on approval
- Galidesivir:
 - Small molecule with broad antiviral activity against numerous high-priority threats
 - Robust development history with over US\$70m in funding to-date from US government
 - Potential to leverage FDA's Animal Rule to fast-track approval in Marburg
- ISLA-101:
 - Pre-clinical work at Monash University highlighted antiviral promise
 - 40+ Phase I, II and III human trials in cancer and respiratory diseases, and deemed safe by regulators
 - Small molecule with activity against all 4 dengue serotypes and other mosquito borne viruses
 - Successfully completed Phase 2a/b clinical trial in dengue infected subjects
- Robust balance sheet allows for execution of program development

AN URGENT THREAT: LETHAL FILOVIRUSES & GLOBAL SECURITY



UNTAMED KILLERS

- High Fatality Rates: Marburg up to 88%, Ebola up to 90% & Sudan up to 47%
- Limited defenses: No widely approved antivirals or vaccines for Marburg; limited countermeasures for Ebola
- BSL-4 classification: requires highest biocontainment
- Dual-use concern: history of weaponization research and intelligence suggests these pose persistent bioterror threat

HUMAN & ECONOMIC IMPACT

- Systemic organ failure
- Hemorrhaging
- Social/economic risk in affected regions
- Bioterror attacks with potential disastrous ramifications





GALIDESIVIR PROGRAM OVERVIEW

- Small molecule with broad antiviral activity against numerous high-priority threats
- Robust development history with over US\$70m in funding to-date from US government
- Confirmed regulatory pathway under the FDA's Animal Rule
- Qualifies for a Priority Review Voucher on approval
- Potential to unlock government stockpile opportunities as a bioterror counter measure

1

Demonstrated activity against **20+ viruses** – many with no available treatment

2

Activity against **potential bioterror** threats

3

Potential markets:

- Government stockpile programs
- Numerous antiviral programs
- Ripe potential for partnering

FDA RESPONSE SIGNIFICANTLY DE-RISKS REGULATORY PATHWAY



Island has the potential to become to first Australian company to gain drug approval via the FDA's Animal Rule

For personal use only



FDA confirmed the Animal Rule pathway is appropriate for developing countermeasures against Marburg virus



Clear guidance provided on clinical program design – enables Island to continue to engage with the FDA and finalise plans ahead of trial commencement



FDA advised that Galidesivir would qualify for a Tropical Disease Priority Review Voucher (PRV) on approval*




Island intends to commence the final Galidesivir animal study in Marburg to advance approval in Q1 CY26 based on final FDA feedback which is expected imminently

*Most recent PRV sold for US\$200m



POTENTIAL REGULATORY PATH



Island is now focused on incorporating all FDA feedback into Galidesivir's clinical development pathway to finalise design and continue regulatory engagement

For personal use only

GALIDESIVIR PROVIDES UNPRECEDENTED SPEED TO MARKET



The FDA has a number of paths for acceleration of pharmaceutical compounds to approval:

- Fast Track Designation
- Breakthrough Therapy Designation
- Accelerated Approval Pathway
- Priority Review
- **Animal Rule Pathway (Special Case)**

The Animal Rule pathway is extremely rare and limited to US National Security threats

The Animal Rule pathway is regulatory hyper-track reserved for the most critical biothreat countermeasures

Marburg is the only Category A bioterror threat gap that remains unfilled within the Strategic National Stockpile (SNS)

All products approved-to-date under the FDA's Animal Rule have secured SNS contracts averaging ~US\$500m in lifetime value


Feature / Category (Expanded)	Oncology Asset (Fast Track)	Galidesivir (Animal Rule)
Human efficacy trials	Multiple Phase 2 and Phase 3 trials required	No human efficacy; NHP survival data accepted
Endpoints	Surrogate biomarkers; must confirm in Phase 3	Animal survival + viral clearance validated by FDA
Safety data	Starting at Phase 1 safety only	2 Phase 1 human safety studies complete
Timeline to approval	6–10 years (even accelerated)	TBD on FDA feedback
Regulatory precedent	Common in oncology approvals	Rare (<15 approvals since 2002), all national security
Commercial outcome	Competitive market entry; slow uptake to peak year sales (PYS in ~5 years)	PRV on approval and SNS procurement (PYS in year 1)
Investor upside	Targeted patient base lowers commercial cost and increases profitability	Low commercial cost structure and high price; US \$200m + long-term SNS revenues

HIGH EFFICACY IN MARBURG NON-HUMAN PRIMATE STUDY



Treated non-human primates showed an overall survival rate of 94% during trial

For personal use only



- 6/6 animals survived when dosed 48 hours post infection
- 6/6 animals survived when dosed 24 hours post infection
- 5/6 animals survived when dosed 1 hour post infection

0/6 untreated animals survived as part of the control group

nature

MARBURG NON-HUMAN PRIMATE STUDY SUMMARY



Study Group	Virus	Survivors (number)	Total subjects	Survival rate (%)
Placebo	Marburg	0	6	0%
Galidesivir (1 hour)	Marburg	5	6	83.33%
Galidesivir (24 hour)	Marburg	6	6	100%
Galidesivir (48 hour)	Marburg	6	6	100%

ANIMAL RULE IS A PROVEN PATH FOR BIOTERROR THREAT COUNTERMEASURES



Company	Product	Year Approved	Disease Treated	SNS Sales (AUD)	Under SNS Contract
Emergent BioSolutions	raxibacumab	2012	Inhalational Anthrax	~\$450M	Yes
Kaléo	AUVI-Q	2012	Anaphylaxis (emergency countermeasure)	~\$100M+	No (contract expired)
Emergent BioSolutions	BioThrax	2015	Anthrax (prophylactic vaccine)	~\$1.2B+ (multi-year)	Yes
Elusys Therapeutics	Anthim	2016	Inhalational Anthrax	~\$320M	Yes
SIGA Technologies	TPOXX	2018	Smallpox	~\$850M+ (ongoing)	Yes
Paratek Pharmaceuticals	Nuzyra	2018	Anthrax (post-exposure prophylaxis)	~\$120M (partial uptake)	Yes (limited scope)
Bavarian Nordic	Jynneos	2019	Smallpox / Monkeypox	~\$300M+	Yes
Chimerix	Tembexa	2021	Smallpox	~\$400M	Yes

Since 2012, the FDA’s Animal Rule approval has led to 8 bioterror countermeasures joining the US Strategic National Stockpile (SNS)

In 7 out of 8 cases, these medical countermeasures continue to remain under SNS contract and have generated ‘lifetime sales’ of between US\$100m - US\$1.2Bn at an average of US\$467m

~US\$600m has been provided through grants to develop a Marburg countermeasure with no tangible results

Marburg is the only Category A biothreat that has no treatment presently available in the Strategic National Stockpile

FDA approval of Galidesivir in Marburg provides a significant opportunity for a Priority Review Voucher as well as a multi-year SNS contract

GALIDESIVIR IS DESIGNED TO PROTECT THE BACKBONE OF NATIONAL RESILIENCE



For personal use only

ILA's stockpile strategy ensures full treatment coverage for the 10,000+ individuals critical to outbreak containment and continuity of government – from POTUS + Cabinet to Essential Infrastructure Leaders.

Tier	Estimated Headcount	Notes
President + Cabinet	~25	Includes POTUS, VP, Cabinet Secretaries
Congressional Leadership	~50	Speaker, Majority/Minority Leaders, Committee Chairs
Supreme Court	9	All Justices
National Security & Defense Heads	~100	Joint Chiefs, DHS, CIA, NSA, FEMA, etc.
Continuity-of-Government Staff	~500–1,000	Includes designated survivors, relocation site personnel
HHS/CDC/FDA Leadership	~200	Key public health and regulatory officials
State Governors + Key Staff	~1000	50 governors + emergency response leads
Tier 1 Healthcare Response Teams	~5,000–10,000	BSL-4 lab staff, frontline responders, quarantine facility personnel
Essential Infrastructure Leaders	~2,000–5,000	Power grid, water, telecom, transport continuity

HIGH-PRIORITY RECIPIENTS FOR GUARANTEED TREATMENT COURSE

TIER 1**-100**

- President + Cabinet
- Congressional Leadership
- Supreme Court

TIER 2**-300**

- National Security & Defense Heads
- Continuity-of-Government Staff
- HHS/CDC/FDA Leadership

TIER 3**-1,000**

- State Governors + Key Staff
- Tier 1 Healthcare Response Teams

TIER 4**-10,000**

- Essential Infrastructure Leaders
- Tier 2 Response Personnel
- Allied Leadership
- Tier 3 Response Personnel
- Other Critical Workers

BROAD SPECTRUM ACTIVITY DEMONSTRATED

Data highlights activity in vitro against multiple RNA viruses from diverse families



Virus Family	Virus	Strain/Variant
Filoviridae	Marburg	Musoke
	Marburg	Ci67
	Marburg	Angola
	Ebola	Kikwit
	Sudan	Boniface
Togaviridae	VEE	SH3
	EEE	FL93-939
	WEE	California
	Chikungunya	AF 15561
Bunyaviridae	Rift Valley Fever	ZH501
	LaCrosse encep	Wisc 1960
	Maporal virus	HV97021050
Arenaviridae	Lassa	Josiah
	Junin	Romero

Virus Family	Virus	Strain/Variant
Paramyxo	Nipah virus	Malaysia
	HRS	A2
	Measles	Chicago
Corona	SARS-CoV	Urbani
	MERS-CoV	Jordan
Orthomyxo	Influenza	pH1N1
Picornaviridae	Rhinovirus-2	HGP
Flaviviridae	West Nile	New York
	Yellow fever	17D
	Jap. Enceph.	SA14
	Powassan Virus	LB
	Dengue 2	New Guinea C
	Zika	PRVABC59



MULTIPLE SHOTS ON GOAL FOR GALIDESIVIR


Virus	Cell culture data	Animal data	Non-human primate efficacy	PRV Eligible	Animal Rule Potential	Strategic National Stockpile Potential
Marburg	✓	✓	✓	✓	✓	✓
Ebola	✓	✓	✓	✓	✓	✓
Sudan	✓			✓	✓	✓
Zika	✓	✓	✓	✓		
Chikungunya	✓			✓		

PRV PRICES CONTINUE TO INCREASE



FDA Priority Review Voucher (PRV) Sale Prices (2022-2026)

- Following expiration of two forms of PRVs the price has dramatically increased over the last 18 months.
- With two programs that are currently PRV eligible, Island is in rare company with a pipeline of molecules with significant near-term value.



NEAR TERM MILESTONES

A number of value catalysts pending over the coming months for Galidesivir



Galidesivir specific milestones	Timeframe
Advance US Government engagement initiatives	Complete
Sign research agreement with gold-standard BSL4 facility and develop clinical trial protocol	Complete
Submit clarifying questions on initial FDA feedback to assist in finalizing Galidesivir clinical program	Complete
Commence strategic appointments to establish Galidesivir Advisory Committee	Ongoing
FDA feedback on protocol clarifying questions	Imminently
Finalise proposed study design following FDA review	Q1 CY26
Commencement of Galidesivir's clinical development prior to NDA preparation	Q1 CY26
Advance opportunities for Galidesivir's broader development in other indications	Ongoing
Explore partnership and international government engagement opportunities	Ongoing

Dates are indicative only, based on current estimates and subject to change



ISLAND
PHARMACEUTICALS




For personal use only

ISLA-101




DENGUE - COMMON AND SPREADING

Global cases of dengue fever rose steeply in 2024
Monthly global cases (millions)



Guardian graphic. Source: WHO. Note: case reporting requirements vary by country

HealthMap: Recent reports of local or imported dengue cases (January 2026)



US\$8.9B estimated impact to the economy from dengue fever



ISLA-101 – BROAD ACTIVITY EVIDENT

- ISLA-101 has demonstrated broad anti-viral activity in in-vitro models
- Demonstrated potent anti dengue-1 activity in in-vitro models using fresh human cells
- Protective in dengue fever and Zika in animal models
- Shown to prevent death in 70% of subjects in extremely lethal animal models
- Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection
- 48 human clinical studies completed in other indications
- ILA's Single Ascending Dose study and further modelling reinforced safety / tolerability and identified dosing for Phase 2 trial




Demonstrated activity against flaviviruses (subgroup of arboviruses) in models of infection



PREVENTING ANIMAL DEATHS FROM LETHAL DENGUE AND PROTECTIVE AGAINST ZIKA

For personal use only



Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model).




DURATION OF VIRAL LOAD-RNAEMIA

ISLA-101 treated subjects exhibited shorter exposure to virus

- Control subjects had detectable viral RNA for ~10.5 days
- Both treatment and preventative cohorts exhibited detectable viral RNA for ~8.5 days – two days shorter than control

Duration of RNAemia






PHASE 2A/B (PROTECT) DESIGN


High-level, unblinded results obtained

- Phase 1 (completed April 2024) achieved all study outcomes relating to safety and dosing, demonstrating benefit of Challenge study approach
- Phase 2a (prophylactic) subjects dosed in October 2024
- Safety Review Council review highlighted:
 - Administering ISLA-101 was safe
 - Study achieved appropriate ISLA-101 blood concentrations
 - Dosed subjects exhibited evidence of antiviral activity versus control
 - Unanimous decision to advance 2b cohort
- 2b (treatment) cohort administered ISLA-101 in February 2025
- Pharmacokinetic analysis of 2b cohort has shown target blood level concentration was achieved in all participants

Phase 2A: Prophylactic (preventative) cohort



Phase 2B: Therapeutic (treatment) cohort






EVIDENCE OF ANTI-DENGUE ACTIVITY


- Using two measures of viral load, a clear reduction in viral load was witnessed in the preventative arm and trend towards viral load reduction in the treatment arm
- Mean peak virus level (RNA) detected a reduction of 10-15x.

Peak



● Group vs PCR
● Group vs PFU

Area Under The Curve



● Group vs PCR
● Group vs PFU

TWO MEASURES OF VIRUS:

RNA (black) as detected by PCR and active virus (red) as detected by plaque forming units.



Island Pharmaceuticals

ASX: ILA

 dfoster@islandpharmaceuticals.com

 islandpharmaceuticals.com

 [@IslandPharma](https://twitter.com/IslandPharma)

 [Island Pharmaceuticals](https://www.linkedin.com/company/island-pharmaceuticals)